Tech Company Financing Transactions
Blue Lake Biotechnology Funding Round
On 10/28/2026, Blue Lake Biotechnology raised $5 million in funding from Bill & Melinda Gates Foundation.
Transaction Overview
Company Name
Announced On
10/28/2026
Transaction Type
Debt
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
111 Riverbend Rd
Athens, GA 30602
USA
Athens, GA 30602
USA
Phone
Email Address
Not Recorded
Overview
Blue Lake Biotechnology is developing intranasal vaccines that harness the full breadth of the immune system to keep people healthy, prevent serious infectious diseases, and protect the lives of vulnerable populations. Blue Lake is developing intranasal vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based system. Our vaccines have the potential to block the transmission of viral infections and reduce their spread. Our platform enables us to make potent yet well-tolerated vaccines that are easy to administer, easy to transport, and easy to manufacture.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Biao He
Chief Financial Officer
Gary Titus
Chief Marketing Officer
Hank Radziewicz
Chief Scientific Officer
Hong Jin
Controller
Helen Zhu
Vice President
Barbara Solow
VP - Bus. Development
Samuel Wu
VP - Regulatory Affairs
Marinka Tellier
Browse more venture capital transactions:
Prev: 10/28/2026: Archera venture capital transaction
Next: 10/28/2026: Firehawk Aerospace venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs